739 results on '"Bertilsson L"'
Search Results
2. Qualitative and quantitative comparison of allergen component-specific to birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test
3. Qualitative and quantitative comparison of allergen component-specific to birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test
4. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity
5. Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation
6. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
7. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
8. The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans
9. INVESTIGATING THE DETERMINANTS OF EFAVIRENZ PHARMACOKINETIC PARAMETERS AFTER LONG TERM TREATMENT WITH AND WITHOUT RIFAMPICIN AMONG TANZANIAN HIV/TB AND HIV PATIENTS: 544
10. IS THERE A NEED FOR EFAVIRENZ DOSAGE ADJUSTMENT DURING CONCOMITANT RIFAMPICIN BASED ANTITUBERCULOSIS THERAPY? FINDINGS FROM THE HIV-TB PHARMAGENE STUDY: 235
11. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels
12. Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy
13. Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?
14. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
15. UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems
16. Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
17. Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine
18. CYP2D6, serotonin, and suicide—a relationship?
19. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
20. In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans
21. Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
22. Effect of Terbinafine and Voriconazole on the Pharmacokinetics of the Antidepressant Venlafaxine
23. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to theCYP2D6 genotype
24. Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects
25. CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir
26. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
27. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
28. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
29. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
30. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians
31. The single nucleotide polymorphism T1128C in the signal peptide of neuropeptide Y (NPY) was not identified in a Korean population
32. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
33. Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders
34. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
35. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance
36. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
37. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment
38. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole
39. Pharmacogenetics of antidepressants: clinical aspects
40. Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
41. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
42. Antidepressants and drug-metabolizing enzymes - expert group report
43. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
44. E-10-Hydroxynortriptyline: Effects and Disposition of a Potential Novel Antidepressant
45. Symposium Genetic Factors Influencing Drug Action
46. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses
47. Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites
48. Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy
49. Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression
50. The action of fenfluramine andp-chloramphetamine on serotonergic mechanisms: A comparative study in rat brain nuclei
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.